Ideaya Biosciences Inc (IDYA) Stock Price, Quote & News

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant,...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 443 6209

Website: www.ideayabio.com

Address:

5000 Shoreline Court, Suite 300, South San Francisco, United States

4Reel Apr. 25 at 8:38 PM

$IDYA the results from this trial frim 4/13 were significant. There ia no standard of care for negative. Results were significantly positive from any prior data or trials and will most likely be the SOC next year. The fact the price jumped to 45 premarket and 38 during market hours and lost all of its gains to 30 shows its undervalued now. Servier was their partner so they could run the entire market for it now if they want. This data still isnt priced in for an unmet treatment that now has proven results. Price should be in the 40s with just this trial data and future SOC data

0 · Reply

hegdaom Apr. 24 at 10:11 PM

$CAPR Deal check — Comparable Deal Check • Sanofi paid ~6x peak sales for Blueprint Medicines ($9.5B deal) • J&J paid ~5x for Intra-Cellular Therapies ($14.6B) • Rare disease deals historically average 4–6x peak revenue CAPR’s profile is arguably stronger than many of these comparables on a per-indication basis given the unmet need in DMD. $SRPT $XBI $IDYA

1 · Reply

kriscory69 Apr. 24 at 9:37 PM

$IDYA soon hopefully next week

0 · Reply

sv__ Apr. 24 at 6:07 PM

$IDYA Added a few this morning.

0 · Reply

hegdaom Apr. 24 at 4:27 PM

$IDYA

0 · Reply

hegdaom Apr. 24 at 4:27 PM

$IDYA

0 · Reply

CDMO Apr. 24 at 3:58 PM

$VRDN $IDYA added both

2 · Reply

4Reel Apr. 24 at 3:23 PM

$IDYA yep getting crushed again today. 34 to 30 in a week. 11% down after eye cancer good data and every analyst upgrading their price targets. Funny how the stock always does opposite of what they say. Im here and im not going anywhere. Cash rich tute owned companies with great pipelines only gain value.

0 · Reply